NeuroSense Provides Update on Nasdaq Listing Compliance
A timely hearing request would stay suspension while NeuroSense seeks additional time to satisfy the $35 million market value requirement.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeuroSense Therapeutics (NRSN) regained Nasdaq minimum bid price compliance but faces delisting after failing to meet the minimum market value requirement. An October 1, 2026 determination identified the $35 million market value requirement as the only outstanding listing criterion. The company missed its September 29 deadline after a 180-calendar-day compliance period.
NeuroSense intends to request a hearing and additional time. A timely request stays suspension and delisting filings pending the panel's decision; the company expects its ordinary shares and warrants to continue trading during that process. The panel may grant an exception of up to 180 days from the determination. Following a 1-for-20 reverse share split, the closing bid price remained at least $1.00 for 10 consecutive business days, September 15–28, 2026, closing the bid-price matter.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointMinimum bid price compliance regained after 10 consecutive business days at $1.00 or greater.
- Minor point. Forward-looking: it has not happened yet and may not happen.Timely hearing request would stay securities suspension and delisting filings pending the panel's decision.
- Minor point. Forward-looking: it has not happened yet and may not happen.PrimeC development remains planned, including Phase 3 PARAGON preparations and a New Drug Submission to Health Canada.
Negative
- Major point$35 million market value requirement remains unmet after the September 29, 2026 compliance deadline.
- Minor point. Forward-looking: it has not happened yet and may not happen.Ordinary shares and warrants face Nasdaq delisting unless NeuroSense requests an appeal.
- Minor point. Forward-looking: it has not happened yet and may not happen.Additional compliance time requires panel discretion, with an exception limited to up to 180 days from the determination.
- Minor point1-for-20 reverse share split preceded restoration of minimum bid price compliance.
Details
Market Reaction – NRSN
On Oct 2, the day this news came out, the latest delayed price for NRSN is 1.65% above the previous close. Our momentum scanner has recorded 5 alerts for this stock so far that day. The latest delayed price is $4.00.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Minimum MVLS requirement
- $35 million
- Continued-listing threshold that NeuroSense had not met
- Initial compliance period
- 180 calendar days
- Period to regain compliance ended September 29, 2026
- Potential exception period
- Up to 180 days
- Nasdaq Hearings Panel discretion from the Staff Determination date
- Minimum bid price
- $1.00 per share
- Minimum bid price requirement; compliance was regained
- Bid-price compliance period
- 10 consecutive business days
- Closing bid price was at least $1.00 from September 15 through September 28, 2026
- Reverse share split
- 1-for-20
- Preceded the period used to regain minimum bid-price compliance
Historical Context
-
Earlier disclosure described Nasdaq deficiencies, a contemplated reverse split, and pursuit of additional compliance time.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
market value of listed securities regulatory
form 25-nse regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company regains compliance with Nasdaq's minimum bid price requirement and intends to request a Nasdaq Hearings Panel hearing to seek additional time to regain compliance with the minimum market value requirement
As previously disclosed, on April 2, 2026, the Staff notified the Company that its MVLS had been below
Appeal Process
The Company intends to request a hearing before a Nasdaq Hearings Panel (the "Panel") in accordance with the procedures set forth in the Nasdaq Listing Rule 5800 Series. Under Nasdaq's rules, a timely hearing request stays the suspension of the Company's securities and the filing of a Form 25-NSE with the
At the hearing, the Company intends to present its plan to regain compliance with Nasdaq's continued listing requirements and to request an exception period to complete that plan. Under Nasdaq's rules, the Panel has discretion to grant an exception of up to 180 days from the date of the Staff Determination. While the hearing process is pending, the Company's ordinary shares and warrants are expected to continue to trade on The Nasdaq Capital Market under the symbols "NRSN" and "NRSNW," respectively.
Minimum Bid Price Compliance Regained
NeuroSense also announced that it has received written notification from the Staff confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of
"Regaining compliance with the minimum bid price requirement is an important step, and we intend to present the Hearings Panel with our plan to meet Nasdaq's remaining continued listing requirement," said Alon Ben-Noon, Chief Executive Officer of NeuroSense. "In parallel, we remain focused on advancing PrimeC in ALS, including preparations for our Phase 3 PARAGON trial and our planned New Drug Submission to Health Canada, as well as other milestones and strategic steps we are evaluating, in order to bring value to our shareholders."
There can be no assurance that the Panel will grant the Company's request for continued listing or an exception period, that the Company will regain compliance with the MVLS Requirement or other applicable Nasdaq continued listing requirements, or that the Company will maintain compliance with the minimum bid price requirement.
About NeuroSense
NeuroSense Therapeutics is a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The Company's lead product candidate, PrimeC, is a novel oral therapy designed to target multiple key biological pathways underlying disease progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism.
NeuroSense has recently completed analysis of long-term follow-up data from its Phase 2b PARADIGM study in ALS, with results published in JAMA Neurology showing slower functional decline in participants who received PrimeC from study start than in those who initially received placebo. The Company also reported changes across multiple biomarkers associated with ALS, including microRNAs, consistent with PrimeC's multi-target mechanism of action.
The Company has received clearance from the U.S. Food and Drug Administration (FDA) to initiate its pivotal Phase 3 PARAGON trial in ALS and is working with the FDA on an optimized study design.
For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.
Forward-Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the Company's intention to timely appeal the Staff Determination, the hearing process, the Company's plan to regain compliance with Nasdaq's continued listing requirement, the continued listing and trading of the Company's securities on The Nasdaq Capital Market, the strategic steps the Company is evaluating, and the potential of PrimeC. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. These risks include the risk that the Panel will not grant the Company's request for continued listing or an exception period; the risk that the Company will not regain compliance with the MVLS Requirement or other Nasdaq continued listing requirements, or will not maintain compliance with the minimum bid price requirement; the risk that the Company's securities will be suspended from trading on, or delisted from, The Nasdaq Stock Market; the potential for delay in the timing of the Phase 3 clinical trial (PARAGON) in ALS; potential delay in the Canadian New Drug Submission; the risk that the Company will not be able to obtain financing on acceptable terms, or at all; the risk that the strategic steps or alternatives the Company is evaluating will not materialize, will not be completed on favorable terms or at all, or will not result in the anticipated benefits to the Company or its shareholders; uncertainty regarding outcomes and the timing of current and future clinical trials; the risk that PrimeC will not advance towards later-stage development; timing for reporting data, including from the study of PrimeC in Alzheimer's disease; that the study will not be successful; and other risks and uncertainties set forth in NeuroSense's filings with the SEC. You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the SEC on March 31, 2026 and NeuroSense's subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurosense-provides-update-on-nasdaq-listing-compliance-302897458.html
SOURCE NeuroSense
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why does NeuroSense face Nasdaq delisting despite regaining bid price compliance?
NeuroSense has not regained compliance with Nasdaq's $35 million minimum market value of listed securities requirement. Its 180-calendar-day compliance period ended September 29, 2026. This was the only continued listing criterion identified in the October 1 determination; the separate minimum bid price matter is closed.
What does NeuroSense plan to do about the Nasdaq delisting determination?
NeuroSense intends to request a Nasdaq Hearings Panel hearing, present its compliance plan and seek additional time. A timely request stays suspension and delisting filings pending the decision. The panel may grant an exception of up to 180 days from the Staff Determination.